J&J Seeks A Priority Review For Depression Drug Esketamine
Executive Summary
Janssen filed an NDA for esketamine nasal spray for treatment-resistant depression with FDA, which could grant a six-month priority review.
You may also be interested in...
J&J Foresees Broad Insurance Coverage For Groundbreaking Spravato Nasal Spray
Datamonitor projects the newly US FDA-approved esketamine product for treatment-resistant depression will reach sales of almost $2bn in the US, Japan and five major European markets.
Keeping Track: J&J Esketamine, Sanofi Caplacizumab Lead Off September Submissions; US FDA Says No To Nucala
The latest drug development news and highlights from our US FDA Performance Tracker.
Key Drug Launches To Plan For In 2019
Around three dozen key late-stage products could reach their first markets in 2019, according to a recent report from Informa Pharma's Biomedtracker. Company execs may need to plan for the disruptive potential of this group of new medicines on established markets and standards of care.